Physician profile
Whitney Griffith
NPI 1578911616
$10,106.76
in general payments reported to CMS, 2019-2025
63 companies · $2,128 in 2025
The $2,128 reported for 2025 was more than what 94% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,628 · 2022: $1,932 · 2023: $1,690 · 2024: $2,728 · 2025: $2,128.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,469 · Education: $77.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,469.12 |
| Education | $77.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $842.27 | 2021-2025 | Rybrevant, Erleada, Darzalex |
| Astrazeneca Pharmaceuticals LP | $736.98 | 2021-2025 | Enhertu, Imfinzi, Tagrisso |
| Novartis Pharmaceuticals Corporation | $680.50 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $576.85 | 2021-2025 | Keytruda, Lynparza |
| Celgene Corporation | $493.78 | 2021-2025 | Reblozyl, Pomalyst, Opdualag |
| Eisai INC. | $433.56 | 2021-2025 | |
| Daiichi Sankyo INC. | $419.02 | 2021-2025 | Enhertu |
| Pfizer INC. | $354.34 | 2021-2025 | |
| Astellas Pharma US INC | $328.15 | 2021-2025 | Padcev, Vyloy, Xospata |
| Seagen INC. | $326.37 | 2021-2023 | Tukysa, Adcetris |
| E.R. Squibb & Sons, L.L.C. | $321.28 | 2021-2025 | Opdivo, Opdualag, Krazati |
| Jazz Pharmaceuticals INC. | $302.09 | 2023-2025 | |
| Lilly USA, LLC | $260.29 | 2022-2024 | Jaypirca, Verzenio, Retevmo |
| Bayer Healthcare Pharmaceuticals INC. | $251.47 | 2021-2025 | |
| Gilead Sciences, INC. | $232.39 | 2022-2025 | Trodelvy |
Show all 63 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $213.65 | 2022-2025 | Libtayo |
| Incyte Corporation | $203.42 | 2021-2025 | Jakafi, Monjuvi, Zynyz |
| Glaxosmithkline, LLC. | $201.24 | 2021-2025 | Ojjaara, Jemperli, Zejula |
| Takeda Pharmaceuticals U.S.A., INC. | $186.51 | 2021-2025 | Fruzaqla, Vpriv, Alunbrig |
| Abbvie INC. | $172.92 | 2021-2025 | |
| Genzyme Corporation | $152.89 | 2021-2025 | |
| Genentech USA, INC. | $151.41 | 2023-2025 | Polivy, Tecentriq |
| Amgen INC. | $140.31 | 2021-2023 | Lumakras |
| Array Biopharma INC | $133.33 | 2021-2025 | Braftovi, Mektovi, Lorbrena |
| Boehringer Ingelheim Pharmaceuticals, INC. | $121.21 | 2021-2025 | |
| Sobi, INC | $108.56 | 2022-2025 | |
| Karyopharm Therapeutics INC. | $107.50 | 2021-2024 | Xpovio |
| Tersera Therapeutics LLC | $103.46 | 2022-2025 | Zoladex |
| Ipsen Biopharmaceuticals, INC | $95.24 | 2021-2025 | Onivyde, Somatuline Depot |
| Dendreon Pharmaceuticals LLC | $94.14 | 2023-2025 | Provenge |
| Taiho Oncology, INC. | $87.37 | 2021-2024 | |
| Emd Serono, INC. | $84.41 | 2021-2025 | |
| Pharmaessentia USA Corporation | $83.98 | 2023-2025 | Besremi |
| Pharmacyclics LLC, An Abbvie Company | $82.80 | 2021-2023 | Imbruvica, Epkinly |
| Alexion Pharmaceuticals, INC. | $81.74 | 2022-2024 | Ultomiris |
| Heron Therapeutics, INC. | $66.96 | 2021-2022 | |
| Rigel Pharmaceuticals, INC. | $62.36 | 2022-2024 | Tavalisse, Rezlidhia |
| Pharmacosmos Therapeutics INC. | $60.09 | 2024 | Cosela |
| Adc Therapeutics America, INC. | $54.39 | 2022-2025 | |
| Myriad Genetic Laboratories, INC. | $54.10 | 2021-2024 | Myrisk |
| Aveo Pharmaceuticals, INC. | $53.16 | 2021-2023 | Fotivda |
| Mirati Therapeutics, INC. | $52.08 | 2023-2024 | Krazati |
| Servier Pharmaceuticals LLC | $46.52 | 2022-2024 | |
| Octapharma USA, INC. | $42.91 | 2023-2024 | Octagam Immune Globulin (Human) |
| Kite Pharma, INC. | $42.53 | 2022-2023 | |
| Novocure INC. | $41.40 | 2024-2025 | Optune Gio, Optune |
| Alnylam Pharmaceuticals INC. | $37.48 | 2021-2023 | Givlaari |
| Iovance Biotherapeutics, INC. | $35.01 | 2025 | Amtagvi |
| G1 Therapeutics, INC. | $34.45 | 2022-2023 | Cosela |
| Kyowa Kirin, INC. | $33.75 | 2021 | |
| Beigene USA, INC. | $25.01 | 2024 | Tevimbra |
| Sun Pharmaceutical Industries INC. | $23.92 | 2025 | |
| Sumitomo Pharma America, INC. | $23.49 | 2024 | Orgovyx |
| Geron Corporation | $19.92 | 2025 | Rytelo |
| Recordati_rare_diseases_inc. | $19.13 | 2025 | Sylvant |
| Csl Behring | $18.77 | 2022 | |
| Legend Biotech USA INC. | $15.96 | 2025 | Carvykti |
| Foundation Medicine, INC. | $14.90 | 2021 | |
| Dova Pharmaceuticals | $14.53 | 2021 | |
| Stemline Therapeutics INC. | $13.90 | 2024 | Orserdu |
| Puma Biotechnology, INC. | $11.82 | 2021 | |
| Blue Earth Diagnostics | $11.44 | 2021 | |
| Global Blood Therapeutics, INC. | $11.35 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Whitney Griffith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.